🔒
Price chart and 15 days of daily prices
Candlestick chart with moving averages, Bollinger bands and MACD.
Register free to view.
Security Profile
- Security Type
- Common Stock
- CUSIP
- 002120202 (prev. 002120103 )
- Market Cap
- Micro Cap
- IPO
- 5/6/2015 · $14.00/share
- Previous Symbol
- LIFE
Business: aTyr Pharma, Inc. is engaged in the discovery and clinical development of innovative medicines for patients suffering from severe rare diseases using its knowledge of Physiocrine biology, a newly discovered set of physiological modulators. The Company’s lead candidate, Resolaris, is a first-in-class intravenous protein therapeutic for the treatment of rare myopathies with an immune component.
Notes: June 28, 2019 -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that its Board of Directors has approved a one-for-14 reverse stock split of its common stock that is scheduled to become effective after trading closes on June 28, 2019. The company’s common stock will begin trading on the Nasdaq Capital Market on a split adjusted basis when the market opens on July 1, 2019. The company’s common stock will continue to trade under the symbol “LIFE.” At the company’s Annual Meeting of Stockholders held on May 8, 2019, the company’s stockholders approved a proposal authorizing the company’s Board of Directors to effect a reverse stock split in a range of 1:3 to 1:15 to help regain compliance with the Nasdaq minimum bid price requirement.
Company Contact
- CEO
- Michael Sullivan
- CFO
- Lynda R. Keeton-Cardno
- Headquarters
- 10240 Sorrento Valley, Suite 300, San Diego, CA 92121
- Phone
- 858-731-8389
- Fax
- 858-731-8394
- Investor Relations
- Ashlee Dunston · 858-731-8389 · adunston@atyrpharma.com